Posted by desolationrower on December 23, 2008, at 11:18:32
In reply to Re: Agomelatin: could 5HT(2c) action be bad for sl » Marty, posted by SLS on December 23, 2008, at 7:16:15
> Hi Marty.
>
> Interesting.
>
> http://www.nature.com/npp/journal/v28/n2/full/1300057a.html
>
> To produce a treatment - whether monotherapy or polypharmacy - that will inhibit the reuptake of 5-HT and simultaneously antagonize 5-HT2a and 5-HT2c receptors in the absence of DA antagonism might be ideal to treat depression.
>
> I hate when researchers feel it necessary to search for a single molecule that will combine all the relevant mechanisms of action. Just give us multiple drugs that are highly specific, complementary, and synergistic.
>
>
> - Scottit sort of goes to many parts of the industry - fda wants a drug that is more effective than other treatments, not just part of a an effective coctail. And doctors want to prescibe one drug not polypharmacy. And the pharm companies don't want a drug that only works when taken with their competitor's drug.
also marty, how has the agometaline affected weight/appetite/metabolism?
I hope researchers beging to look at conditional effects of recptors more as i don't think the always have simple linear reltaionship: MORE agonism=MORE activation or whatever. I would like if there was a wiki database of research - as a researcher publishes their study, they must update the encyclopedia - less to create articles, but to have references to the relevant research. I'm sure there are many problems with such an idea.
-d/r
poster:desolationrower
thread:869924
URL: http://www.dr-bob.org/babble/20081223/msgs/870477.html